Primary cutaneous plasmacytoma: treatment with intralesional tumour necrosis factor-alpha

Br J Dermatol. 1992 Apr;126(4):395-7. doi: 10.1111/j.1365-2133.1992.tb00688.x.

Abstract

We report a case of primary multiple cutaneous plasmacytomas, without underlying multiple myeloma, treated with intralesional tumour necrosis factor-alpha (TNF-alpha). A marked reduction in tumour size, with no significant adverse effects, suggests that intralesional TNF-alpha is an effective treatment for non-solid malignant tumours. Extramedullary plasmacytoma, especially involving the skin as a primary site, has rarely been reported in the English literature. We describe the ninth reported case of multiple cutaneous plasmacytomas without underlying multiple myeloma. Intralesional tumour necrosis factor-alpha (TNF-alpha) was used to treat this disease and its anti-tumour effect quantitatively evaluated by comparing the tumour size and histological change before and after treatment.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Drug Administration Schedule
  • Female
  • Humans
  • Injections, Intralesional
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / pathology
  • Recombinant Proteins / administration & dosage
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / pathology
  • Tumor Necrosis Factor-alpha / administration & dosage*

Substances

  • Recombinant Proteins
  • Tumor Necrosis Factor-alpha